title: Efficacy of misoprostol in the treatment of tinnitus in patients with diabetes and/or hypertension.
abstract: OBJECTIVE
  To determine the efficacy of the prostaglandin E1 analogue misoprostol in the treatment of tinnitus in diabetic and/or hypertensive patients.
  
  
  METHODS
  Double-blind, randomized, placebo-controlled trial.
  
  
  METHODS
  Tertiary care referral center.
  
  
  METHODS
  The subjects were 42 patients with hypertension and/or diabetes mellitus who had chronic tinnitus and had experienced tinnitus symptoms for a minimum of 6 months. Twenty-eight patients were randomly assigned to Group I (misoprostol treatment), and 14 patients to the Group II (placebo treatment). Misoprostol therapy was started at 200 microg per day, and was increased 200 microg every 7 days until a dose of 800 microg per day was reached. The same numbers of placebo tablets were given to the control group using the same schedule. Both groups were treated for 1 month. The changes in objective and subjective tinnitus findings from baseline to 1 month were assessed, and the group results were compared. The chi(2)-test, student's t-test and paired-samples t-test were used to analyze the study.
  
  
  RESULTS
  At the completion of treatment, objective assessment showed that tinnitus loudness decreased in 13 (46%) of the 28 patients in the experimental group, whereas this was observed in only two (14%) of the 14 subjects in the placebo group. Subjective tinnitus scoring revealed improvement rates of 29 and 14% for the misoprostol and placebo groups, respectively. When t-test relating to difference between rates were performed, the difference between improvement rate for tinnitus loudness of the experimental group and control group was found to be statistically significant (P = 0.05), but difference between improvement rate based on subjective tinnitus scoring was insignificant (P = 0.22).
  
  
  CONCLUSIONS
  Misoprostol is an effective and safe treatment for chronic tinnitus in hypertensive and/or diabetic patients. Our results are encouraging, but further studies of larger series are needed.
authors.affiliation: Department of Otolaryngology Head and Neck Surgery, Baş kent University Faculty of Medicine, Ankara, Turkey.
authors.forename: Babur
authors.initials: B
authors.lastname: Akkuzu
authors.forename: Ismail
authors.initials: I
authors.lastname: Yilmaz
authors.forename: Ozcan
authors.initials: O
authors.lastname: Cakmak
authors.forename: Levent N
authors.initials: LN
authors.lastname: Ozluoglu
mesh_terms: D000328:Adult; D000368:Aged; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications*; D008297:Male; D008875:Middle Aged; D016595:Misoprostol / Q000009:adverse effects / Q000627:therapeutic use*; D012720:Severity of Illness Index; D014012:Tinnitus / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D016595:Misoprostol